Technology

ENHANMIX^® 

PrimeLink Bio's ADC technology platform ENHANMIX^® is a versatile and highly hydrophilic platform designed to seamlessly integrate with existing tools for each ADC module. It is compatible with a wide range of current technologies, and is capable of conjugating various payloads with diverse mechanisms of action (MOAs), regardless of their hydrophobicity. ENHANMIX^® also enables precise control over the drug-to-antibody ratio (DAR), ensuring optimal efficacy. HydramiX ADC exhibits excellent stability in circulation, with favorable pharmacokinetic profiles and outstanding tolerability.

At PrimeLink, we take a targeted approach to ADC design, tailoring each ADC to its specific tumor target. ENHANMIX^® generates an ADC pool with diverse molecular structures, including different payloads and DARs, all aligned with advanced ADC technologies and target biology:

• Antibodies: We employ a range of antibody formats, including monoclonal, bispecific, nanobody, and scFv, to match the target's biological profile.
• Linker-Payload Technology: Our proprietary linker technology breaks the constraints of fixed linker-payload combinations, enabling compatibility with any clinically validated payload and significantly expanding toxin MOA diversity. 
• Site-specific conjugation: Our proprietary linker technology enables precise site-specific conjugation, allowing us to produce homogeneous ADCs with greater consistency and control.
• Flexible DARs: With our platform, we could achieve DARs up to 24, while ensuring strong CMC developability.
• Controlled Payload Release: Our technology enables precise delivery to the tumor and release of the payloads for optimized therapeutic impact.
• Next generation ADC expansion: Leveraging our extensive expertise in linker design and development, we have expanded our ADC portfolio to include innovative formats such as bispecific ADCs, immune-stimulating antibody conjugates (ISACs), protein-degrader antibody conjugates (DACs), dual-drug ADCs and antibody-oligonucleotide conjugates (AOCs).

The diversified ADC pool is designed to enhance our ability to address the challenge of tumor heterogeneity. Through in-house cascade screening platform, we identify optimized ADC candidates for further development.